: iStockAnalyst.com Symbols Feed

King Beats, But Earnings Down

Thu, 05 Nov 2009 20:08:54 GMT

King Pharmaceuticals, Inc. (KG) reported third quarter earnings of 29 cents per share, beating the Zacks Consensus Estimate by 2 cents. Despite revenues increasing 19.3% from the year-ago period, earnings declined 25.6% from the year-ago quarter mainly due to higher operating expenses.[More...]

Top 40 Rated Emerging Bio-Pharma Stocks

Mon, 22 Dec 2008 16:22:00 GMT

The accompanying table (click to enlarge) highlights the Top 40 Rated stocks (sorted alphabetically) in the ETF Innovators (ETFI) Emerging Bio-Pharma Index of biotech and pharmaceutical companies with market caps of $200M-$1.5B. The rating system factors in each company's number of innovative clinical pipeline + marketed products, market cap weighting, and historical stock price return. The Emerging Bio-Pharma Index has outpaced benchmark ETFs such as iShares Nasdaq[More...]

Periodicals Wrap-Up for Monday, August 18

Mon, 18 Aug 2008 13:45:00 GMT

Posted by Optiondragon for myhappytrading, a social network made by traders for traders.[More...]

NASDAQ Technical Picture - Lowest Close Since Oct. 2006 - Mar 7 2008 10:05AM

Fri, 07 Mar 2008 14:00:27 GMT

NASDAQ Technical Picture - Lowest Close Since Oct. 2006 - Mar 2 2008 11:12PM

Mon, 03 Mar 2008 03:06:42 GMT

Friday's close was the lowest since October 2006. The NASDAQ has been carving a symmetrical triangle for 5 weeks. Symmetrical triangles are generally continuation patterns, so Friday's action was no surprise, and probably a welcome relief after all the narrow range trade as price moved closer to the apex. Prices gapped some 20 points lower and continued lower on higher volume in afternoon to end the session off by 60 pts. or 2.6%. All major sectors participated in the drubbing.The Feb. low is less than 20 pts. away, followed by a retest of the J[More...]

Another Swift Recovery?

Mon, 04 Feb 2008 14:20:13 GMT

Good morning. Following the best weekly gain in the S&P 500 since 2003, we're set for a mixed open amid strength in overseas markets, some earnings (see HUM and ADM), and news that Google has offered to help Yahoo! fight off Microsoft's unsolicited offer.[More...]

Omrix Biopharma (NASDAQ:OMRI): Oppenheimer upgrades to Buy

Thu, 09 Aug 2007 16:01:34 GMT

I'm now hearing Oppenheimer is out with an upgrade on Omrix Biopharma (NASDAQ:OMRI),...[More...]

Pre-Market - Thursday August 9th

Thu, 09 Aug 2007 15:59:42 GMT

Futures indicate a sharply lower open for the mkt on renewed concerns about liquidity/credit risks. BNP Paribas has suspended withdrawals from three of its funds valued at around $2.1 bln due to an inability to fairly value their holdings on account of the turmoil in the U.S. credit mkt. Even though BNP's exposure (which is less than 1.0% of total assets) seems relatively small, the announcement serves as a clear reminder that the headline risk remains real and that the volatility in trading conditions will persist. This morning was also the release of July Retail Sales figures, which are coming in weaker than expected amid sluggish sales at teen-apparel shops. WMT, however, reported sales of 1.6% which met expectations. Dow futures are currently -180; Nasdaq futures are currently -22.5; S&P futures are currently -22.8.Notable pre-market Calls include Upgrades<[More...]

Omrix Biopharma (NASDAQ:OMRI): Actionable call alert!

Thu, 09 Aug 2007 13:59:20 GMT

Several firms are out in defense of Omrix Biopharma (NASDAQ:OMRI) after the biosurgical and passive immunotherapy products maker posted a 71 percent fall in quarterly profit partly hurt by certain unrecognized and deferred revenue and lowered its total product sales view for 2007, pushing shares down 20 percent. The uncertainty related to future shipment of Intravenous Immunoglobulin (IVIG) to an European Union country, as well as related unrecognized revenue resulted in the company cutting its full-year product sales view.Omrix said it was not certain as to when it could record the revenue or if it could even continue to sell the product in that country in 2007:- Cowen notes Omrix reported 2Q results below estimates but they believe fundamentals remain fully intact for above average growth beginn[More...]

NASDAQ Technical Picture - Bulls Regain Momentum

Thu, 09 Aug 2007 06:10:05 GMT

Early strength was triggered by solid earnings in a few names including CSCO, which helped the NAZ outperform. Also some[More...]

Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.

Sat, 27 Dec 2008 14:04:00 GMT

Johnson & Johnson today announced that stockholders of Omrix Biopharmaceuticals, Inc. tendered approximately 16,749,152 shares of Omrix common stock, including approximately 1,293,924 shares subject to guaranteed delivery procedures, representing approximately 97.8% of Omrix's outstanding common stock. According to the terms of Johnson & Johnson's tender offer, shares that were validly tendered and not withdrawn have been accepted for payment. The tender offer expired at 12:00 midnight on Dec. 26, 2008, and was not extended.[More...]

Johnson & Johnson Extends Tender Offer for Omrix Biopharmaceuticals, Inc.

Fri, 19 Dec 2008 21:38:00 GMT

Johnson & Johnson Extends Tender Offer for Omrix Biopharmaceuticals, Inc.[More...]

Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix

Thu, 11 Dec 2008 21:36:00 GMT

Johnson & Johnson today announced that the Israeli General Director of the Antitrust Authority has approved Johnson & Johnson's proposed acquisition of Omrix Biopharmaceuticals, Inc. , under the Restrictive Trade Practices Law 5748-1988 of Israel.[More...]

Law Offices of Brian M. Felgoise, P.C. Announces Class Action Lawsuit on Behalf of Shareholders of Omrix Biopharmaceuticals, Inc. -- OMRI

Wed, 03 Dec 2008 17:41:00 GMT

PHILADELPHIA, PA -- -- 12/03/08 -- Law Offices of Brian M. Felgoise, P.C. announces that a class action has been commenced on behalf of shareholders of Omrix Biopharmaceuticals, Inc. in connection with the offer by Johnson & Johnson to acquire all of the outstanding shares of OMRI.[More...]

Johnson & Johnson Begins Tender Offer to Acquire Omrix

Tue, 25 Nov 2008 16:34:00 GMT

Johnson & Johnson is commencing today, through a new wholly-owned subsidiary, Binder Merger Sub, Inc., a cash tender offer to purchase all outstanding shares of common stock of Omrix Biopharmaceuticals, Inc. . Johnson & Johnson reported on November 24, 2008, its intent to acquire Omrix.[More...]

Johnson & Johnson Announces Definitive Agreement to Acquire Omrix

Mon, 24 Nov 2008 10:26:00 GMT

Omrix's Biopharmaceutical Expertise Complements ETHICON's Industry-Leading Surgery Portfolio[More...]

Omrix Biopharmaceuticals to Webcast Presentation at Credit Suisse Annual Healthcare Conference

Thu, 06 Nov 2008 17:43:00 GMT

Omrix Biopharmaceuticals, Inc. (“Omrix”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that Nissim Mashiach, President & Chief Operating Officer, is scheduled to give a company presentation at the Credit Suisse Annual Global Healthcare Conference on Friday, November 14, 2008 at 9:00 a.m. Mountain Standard Time; 11:00 am Eastern Standard Time at the Arizona Biltmore Resort & Spa in Phoenix, Arizona.[More...]

Omrix Biopharmaceuticals Announces Third Quarter 2008 Financial Results

Thu, 06 Nov 2008 11:09:00 GMT

Omrix Biopharmaceuticals, Inc. (“Omrix” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, today announced financial results for the third quarter ended September 30, 2008:[More...]

Omrix Biopharmaceuticals to Webcast Presentation at Rodman & Renshaw Annual Healthcare Conference

Tue, 04 Nov 2008 12:18:00 GMT

Omrix Biopharmaceuticals, Inc. (“Omrix”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that Nissim Mashiach, President & Chief Operating Officer, is scheduled to give a company presentation at the Rodman & Renshaw Annual Healthcare Conference on Monday, November 10, 2008 at 2:25 p.m. ET at the New York Palace Hotel in New York City.[More...]

Omrix Biopharmaceuticals Reschedules its Third Quarter 2008 Financial Results and Conference Call to an Earlier Time on November 6, 2008

Mon, 03 Nov 2008 12:28:00 GMT

OMRIX Biopharmaceuticals, Inc. (“OMRIX” or the “Company”) (NASDAQ: OMRI), a fully-integrated biopharmaceutical company that develops and markets biosurgical and immunotherapy products, announced today that it has rescheduled the announcement of its financial results and accompanying conference call for the third quarter ended September 30, 2008 to an earlier time. The Company will now announce its financial results before the opening of the U.S. financial markets on Thursday, November 6, 2008 and the accompanying conference call to discuss the results will be held at 8:00 am ET; 5:00 am PT.[More...]